Drug Discovery World

MAY 6, 2024

Thanks to a prestigious academic legacy, Europe has long been a dominant region for life sciences. Europe is traditionally a life sciences powerhouse, with a strong tradition in pharmaceutical discovery. The oldest, still active pharmaceutical company worldwide, Merck, started life in 1668 in Darmstadt, Germany.

Drugs 59

Drugs Life Science Gene Editing Gene 59

XTalks

DECEMBER 20, 2023

As we step into 2024, the life sciences continue to evolve at an unprecedented pace, driven by technological innovation, a deeper understanding of human biology and the application of new technologies in areas like drug development and health wearables. These companies are at various stages of research and clinical trials.

Life Science 119

Life Science Gene Editing Development Clinical Trials 119

Drug Discovery World

OCTOBER 16, 2023

Despite the overall reduction in major pharma R&D centres in the UK, global pharma companies continue to engage with academic and biotech organisations here, particularly in hotspots such as the Golden Triangle, the Northwest, and Scotland, through the strong networks that have been developed between these organisations.

Drugs 75

Drugs Life Science Gene Therapy Genome 75

Pharmaceutical Technology

FEBRUARY 13, 2023

This is particularly the case for pediatric forms of epilepsy where gene editing techniques like Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) are becoming more important, says Ferraro. In his work, Ferraro focuses on the links between gene variations and different responses to drugs.

Research 264

Research Gene Gene Therapy Genome 264

Drug Discovery World

MAY 29, 2024

Closed Loop Medicine and Pharmanovia TechBio Closed Loop Medicine and pharma company have initiated the OptiZest study and recruited the first patient. Making better use of data by integrating life science expertise with AI solutions is a promising approach to simplify and accelerate biopharma drug discovery and manufacturing progress.

Drugs 52

Drugs Gene Editing Life Science Genome 52

Drug Discovery World

JANUARY 26, 2023

As such, 2022 saw a marked fall in ROI for global pharmaceutical companies and their research and development activities. According to research from Deloitte 1 , the average ROI in R&D for global pharma companies fell to just 1.2% in 2022, a steep decline compared to the record 6.8% the industry experienced in 2021.

Development 98

Development Drugs Clinical Trials Clinical Trials 98